CLAIMS

1- Use of a virus-like particle comprising a lipoprotein envelope including a viral fusogenic glycoprotein, for the manufacture of a medicament for treating cancer, wherein said virus-like particle contains cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) packaged into said virus-like particle.

2- The use according to claim 1, wherein the virus-like particle further comprises a capsid from retroviridae.

3- The use according to claim 1 or 2, wherein the viral fusogenic glycoprotein is a glycoprotein from retroviridae (including lentivirus and retrovirus), herpesviridae, poxviridae, hepadnaviridae, flaviviridae, togavoridae, coronaviridae, hepatitis D virus, orthomyxoviridae, paramyxoviridae, filoviridae, rhabdoviridae, bunyaviridae, or orthopoxivridae (e.g. variola), preferably from orthomyxovirus, retroviruses, rhabdovirus.

4- The use according to any one of claims 1-3, wherein the viral fusogenic glycoprotein is a glycoprotein from HIV (Human Immunodeficiency Virus) including HIV-1 and HIV-2, Influenza including Influenza A (e.g. subtypes H5N1 and H1N1) and Influenza B, thogotovirus, or VSV (Vesicular Stomatitis Virus).

5- The use according to any one of claims 2-4, wherein the retroviral capsid is from retroviridae, preferably lentivirus and retrovirus.

6- The use according to any one of claims 2-4, wherein the retroviral capsid is from HIV or MLV (Murine Leukemia Virus).

7- The use according to any one of claims 1-6, wherein the cyclic dinucleotides are cGAMP (2'-3'-cyclic GMP-AMP).

8- The use according to any one of claims 1-6, wherein the cyclic dinucleotides are cGAMP (3'-3'-cyclic GMP-AMP).

9- The use according to any one of claims 1-8, wherein the virus-like particle further comprises an antigen or any other protein or nucleic acid of interest, preferably a tumor associated antigen or a combination thereof.

10- The use according to any one of claims 1-9 wherein the virus-like particle is to be used in combination with an antigen or a therapeutic active agent.

11- The use according to any one of claims 1-10, wherein the virus-like particle is to be administered by intravenous, subcutaneous or intratumoral route.

12- The use according to claim 11, wherein the virus-like particle is to be administered by intratumoral route.

13- A pharmaceutical, vaccine or veterinary composition comprising a virus-like particle as defined in any one of claims 1-10 and at least one tumor associated antigen.